Encysive Dispute Resolution Request For Thelin Negged By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Securing approval by conducting an additional Phase III study as requested by FDA would take years, CEO Cole tells “The Pink Sheet” DAILY.
You may also be interested in...
Encysive Rules Out FDA Dispute Resolution Path For Thelin NDA
Firm expects to have 35 sales reps for European, Canadian launch of Thelin by early next year, CEO says.
Encysive Rules Out FDA Dispute Resolution Path For Thelin NDA
Firm expects to have 35 sales reps for European, Canadian launch of Thelin by early next year, CEO says.
Encysive To Enter Dispute Resolution With FDA Over Third Thelin “Approvable” Letter
Company asserts that FDA’s data analysis of STRIDE-2 trial for Thelin does not follow special protocol assessment agreement.